Clinical trials in Stuttgart – page 58

982 clinical trials in Stuttgart, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Stuttgart at a glance

982

clinical trials

Research sites3

Quick filters

982 trials in Stuttgart

Open in trial search

Gastrointestinal stromal tumour

Not recruiting

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Imatinib
Sponsor:Region Skane

Contact Research Centre

Metastatic neoplasm+1

Not recruiting

Study on Treating Advanced Cancers with BRAF Mutations Using Sorafenib and Trametinib for Patients with Impaired Kinase Activity

Registered drugNo placebo

Study on Treating Advanced Cancers with BRAF Mutations Using Sorafenib and Trametinib for Patients with Impaired Kinase Activity

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Sorafenib
Sponsor:Medical Center - University Of Freiburg

Contact Research Centre

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:Day One Biopharmaceuticals Inc.

Contact Research Centre

Acoustic neuroma

Not recruiting

Study on Nimodipine for Hearing Preservation in Patients Undergoing Acoustic Schwannoma Surgery

Registered drugNo placebo

Study on Nimodipine for Hearing Preservation in Patients Undergoing Acoustic Schwannoma Surgery

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Nimodipine
Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Contact Research Centre

Prophylaxis against transplant rejection

Not recruiting

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Tacrolimus
Sponsor:Universitaetsklinikum Regensburg AöR

Contact Research Centre

Renal cell carcinoma

Not recruiting

Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment

Registered drugNo placebo

Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Triple negative breast cancer

Not recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Rectal cancer

Not recruiting

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Heidelberg University

Contact Research Centre

Acute lymphocytic leukaemia

Not recruiting

Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Blinatumomab
Sponsor:Goethe University Frankfurt

Contact Research Centre

Triple negative breast cancer

Not recruiting

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Stuttgart

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer, diffuse large B-cell lymphoma, and bladder cancer treatments. Studies evaluate novel therapeutic approaches including targeted therapies and immunotherapy combinations.

Advanced Cancer Treatments
Immunotherapy Studies
Novel Drug Combinations

Several trials investigating breakthrough treatments for various forms of leukemia and solid tumors.

02 Immunology and Vaccines

Research focusing on cytomegalovirus prevention and influenza vaccination in different age groups. Studies evaluate innovative vaccine formulations and immune responses.

Vaccine Development
Immune Response Studies
Preventive Medicine

Trials aim to enhance vaccine efficacy and improve protection against infectious diseases.

03 Metabolic and Eye Disorders

Studies addressing weight management and various eye conditions including retinal disorders. Research includes innovative treatments for macular degeneration and vision preservation.

Weight Management Therapies
Retinal Disease Treatment
Vision Preservation

Focus on developing treatments that improve patient outcomes and quality of life.

Back to Germany All countries